Citi added an “upside 90-day catalyst watch” on shares of Zenas BioPharma (ZBIO) while keeping a Buy rating on the shares with a $46 price target ahead of the early January Phase 3 INDIGO readout in immunoglobulin G4-related disease. Citi believes obexlimab is positioned to show a statistically significant reduction in flares relative to placebo.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBIO:
- Zenas BioPharma rises 10.6%
- Promising Developments in Zenas BioPharma’s Orelabrutinib Drive Buy Rating Amidst Competitive Advantage and Expected Share Price Upside
- Buy Rating Reaffirmed for Zenas BioPharma: Promising Orelabrutinib Developments and Autoimmune Platform Potential
- Zenas BioPharma Approves 2026 Inducement Plan
- Zenas BioPharma falls -13.0%